Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?

被引：1
|
作者：
van der Wekken, Anthonie J. [1 ]
Kok, Klaas [2 ,3 ]
Groen, Harry J. M. [1 ]
机构：
[1] Univ Groningen, Dept Pulm Dis, Groningen, Netherlands
[2] Univ Groningen, Dept Genet, Groningen, Netherlands
[3] Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷
关键词：
CRIZOTINIB; RESISTANCE; INHIBITOR;
D O I：
10.21037/jtd.2018.06.45
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：S2130 / S2132
页数：3
相关论文
共 50 条
  • [41] Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
    Shaw, Alice T.
    Kim, Dong-Wan
    Mehra, Ranee
    Tan, Daniel S. W.
    Felip, Enriqueta
    Chow, Laura Q. M.
    Camidge, D. Ross
    Vansteenkiste, Johan
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin
    Liu, Geoffrey
    Santoro, Armando
    Lau, Yvonne Y.
    Goldwasser, Meredith
    Boral, Anthony L.
    Engelman, Jeffrey A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (13): : 1189 - 1197
  • [42] Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
    Shen, Liang
    Ji, Hong-Fang
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (26): : 2537 - 2537
  • [43] Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus
    Cappuzzo, Federico
    Moro-Sibilot, Denis
    Gautschi, Oliver
    Boleti, Ekaterini
    Felip, Enriqueta
    Groen, Harry J. M.
    Germonpre, Paul
    Meldgaard, Peter
    Arriola, Edurne
    Steele, Nicola
    Fox, Jesme
    Schnell, Patrick
    Engelsberg, Arne
    Wolf, Juergen
    LUNG CANCER, 2015, 87 (02) : 89 - 95
  • [44] COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEY
    Oksuz, E.
    Malhan, S.
    Yanik, L.
    Koc, E.
    Erdogan-Ciftci, E.
    Guler, B.
    Orfanos, P.
    VALUE IN HEALTH, 2018, 21 : S40 - S40
  • [45] Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials
    Hao-chuan Ma
    Yi-hong Liu
    Kai-lin Ding
    Yu-feng Liu
    Wen-jie Zhao
    Yan-juan Zhu
    Xue-song Chang
    Ya-dong Chen
    Zhen-zhen Xiao
    Ya-ya Yu
    Rui Zhou
    Hai-bo Zhang
    BMC Cancer, 21
  • [46] Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials
    Ma, Hao-chuan
    Liu, Yi-hong
    Ding, Kai-lin
    Liu, Yu-feng
    Zhao, Wen-jie
    Zhu, Yan-juan
    Chang, Xue-song
    Chen, Ya-dong
    Xiao, Zhen-zhen
    Yu, Ya-ya
    Zhou, Rui
    Zhang, Hai-bo
    BMC CANCER, 2021, 21 (01)
  • [47] Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer
    Shiihara, Jun
    Ohyanagi, Fumiyoshi
    Amari, Hikari
    Toda, Minemichi
    Tahara, Hiroki
    Yuzawa, Motoi
    Maeda, Yuki
    Nomura, Motoko
    Mizushina, Yoshiko
    Nagai, Yoshiaki
    Ohta, Hiromitsu
    Yamaguchi, Yasuhiro
    THORACIC CANCER, 2021, 12 (17) : 2420 - 2423
  • [48] Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions
    Laird Cameron
    Benjamin Solomon
    Drugs, 2015, 75 : 1059 - 1070
  • [49] ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism
    Zer, Alona
    Moskovitz, Mor
    Hwang, David
    Hershko-Klement, Anat
    Fridel, Ludmila
    Korpanty, Grzegorz
    Dudnik, Elizabeth
    Peled, Nir
    Shochat, Tzippy
    Leighl, Natasha
    Liu, Geoffrey
    Feld, Ronald
    Burkes, Ronald
    Wollner, Mira
    Tsao, Ming
    Shepherd, Frances
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S326 - S327
  • [50] ALK-rearranged non-small cell lung cancer is associated with a high rate of venous thromboembolism
    Zer, A.
    Hershko-Klement, A.
    Hwang, D.
    Korpanty, G.
    Leighl, N.
    Liu, G.
    Feld, R.
    Burkes, R.
    Tsao, M.
    Shepherd, F.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S134 - S134
12345